© 2022 BioMarin. All rights reserved.

Current Studies


 

Study 331-201

Recruiting

Study 331-201: A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING1, in Subjects with Hereditary Angioedema (HAE) due to Human C1 Esterase Inhibitor (C1-INH) Deficiency

  • Indication

    Hereditary Angioedema (HAE)

  • Investigational therapeutic

    BMN 331

  • Study Type

    Phase 1/2

  • Goal

    This open label, two-part study aims to establish the safety, tolerability, and efficacy of BMN 331

  • Status

    This study is currently recruiting participants

View Study 331-201 Now